Venrock Healthcare Capital Par Purchases 4,137 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par purchased 4,137 shares of the company’s stock in a transaction on Monday, February 10th. The stock was bought at an average cost of $9.14 per share, for a total transaction of $37,812.18. Following the acquisition, the insider now directly owns 5,090,582 shares of the company’s stock, valued at $46,527,919.48. This represents a 0.08 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Friday, February 7th, Venrock Healthcare Capital Par bought 73,649 shares of KalVista Pharmaceuticals stock. The stock was bought at an average price of $9.29 per share, for a total transaction of $684,199.21.
• On Monday, February 3rd, Venrock Healthcare Capital Par bought 14,562 shares of KalVista Pharmaceuticals stock. The shares were bought at an average cost of $9.22 per share, with a total value of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par purchased 43,707 shares of KalVista Pharmaceuticals stock. The stock was bought at an average cost of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Stock Up 0.6 %

KALV stock opened at $9.33 on Thursday. The company has a 50 day moving average of $8.74 and a two-hundred day moving average of $10.58. The company has a market cap of $461.09 million, a price-to-earnings ratio of -2.56 and a beta of 0.85. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $16.88.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.01. On average, research analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current year.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in KALV. China Universal Asset Management Co. Ltd. grew its stake in shares of KalVista Pharmaceuticals by 67.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after buying an additional 3,328 shares in the last quarter. Martin Worley Group bought a new stake in KalVista Pharmaceuticals in the fourth quarter worth approximately $86,000. Intech Investment Management LLC bought a new stake in KalVista Pharmaceuticals in the third quarter worth approximately $126,000. SG Americas Securities LLC acquired a new position in shares of KalVista Pharmaceuticals during the 3rd quarter worth $153,000. Finally, Quest Partners LLC bought a new position in shares of KalVista Pharmaceuticals during the 3rd quarter valued at $175,000.

Wall Street Analyst Weigh In

Several brokerages have commented on KALV. HC Wainwright reiterated a “buy” rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, December 6th. Citizens Jmp raised shares of KalVista Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of KalVista Pharmaceuticals in a research note on Monday, December 9th. Bank of America started coverage on KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price for the company. Finally, TD Cowen began coverage on KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price target on the stock. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $23.80.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).